Quantumzyme Corp., a biotransformation company focused on sustainable pharmaceutical manufacturing, provided an overview of corporate developments during 2025 and outlined operational priorities for 2026, including a proposed corporate name change to Quantum Genesis AI Corp. The company advanced internal research efforts related to enzyme engineering and biocatalytic process development for pharmaceutical and specialty chemical applications, with all activities remaining in the research and evaluation stage. Throughout 2025, Quantumzyme remained focused on foundational research, capital discipline, and regulatory compliance while navigating challenges typical of early-stage biotechnology development.
During 2025, the company expanded its internal focus on artificial intelligence and computational methods to support enzyme research and development activities. Quantumzyme evaluated data-driven approaches, including machine learning techniques and computational modeling, as tools to assist in enzyme discovery, structure-function analysis, and research prioritization. These artificial intelligence initiatives are intended to complement existing laboratory research by improving experimental design and data analysis efficiency, though they remain at a research and evaluation stage focused on internal decision support rather than commercial software development. The company believes integrating computational methods into its research workflow may help guide future development efforts, but acknowledges these initiatives are exploratory and subject to technical, financial, and operational limitations.
In late 2025, Quantumzyme's Board of Directors approved a proposal to change the company's legal name to Quantum Genesis AI Corp. and seek a corresponding trading symbol change, reflecting greater emphasis on computational and data-driven approaches within enzyme research activities. The company has submitted required documentation for this corporate action, which remains subject to FINRA approval and completion of applicable regulatory requirements. While there can be no assurance regarding timing or approval, the name and symbol change are expected to be completed during the first quarter of 2026. For more information, investors can visit the company's profile at https://www.otcmarkets.com/stock/QTZM.
Looking ahead to 2026, Quantumzyme expects to focus on several strategic priorities. The company plans to advance enzyme candidates and biocatalytic pathways through internal testing, optimization, and feasibility assessment while maintaining a research-stage development posture. Computational and AI tool development will continue, with refinement of modeling and data-driven research tools to support enzyme research and improve internal efficiency. Quantumzyme will evaluate potential collaboration, licensing, or development opportunities with third parties, including pharmaceutical and chemical industry participants, though any arrangements remain exploratory unless formally executed. The company also plans increased visibility through scientific forums, industry events, and investor communications consistent with regulatory requirements, while assessing longer-term corporate objectives including reporting status and capital planning.
The company cautions that its 2026 objectives are subject to various risks and uncertainties, including technical challenges, capital availability, regulatory considerations, and market conditions. Throughout 2025, Quantumzyme announced publication of U.S. and international patent applications related to enzymatic processes under development, though patent applications remain pending with no assurance that patents will be granted or that resulting intellectual property will provide commercial protection. The company updated its corporate website and public communications to more clearly describe its business focus, development approach, and long-term objectives, supporting transparency for shareholders and the market. Additional information is available at https://www.quantumzymecorp.com.
